Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Investor Presentation (January 2019)
20 slides from Collegium Pharmaceutical's investor presentation, Jan 7, 2019
Slide 1: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts,“ “forecasts,” "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 2: Mission Statement
Mission Statement Collegium is committed to being the leader management in responsible pain 3
Slide 3: Experienced Management Team & Board of Directors
Experienced Management Team & Board of Directors Collegium Board of Directors eder a Therapeutics; of Cadence als 4 Joseph Ciaffoni President & CEO, Collegium Pharmaceutical Michael Heffernan Chairman of the Board & Collegium Founder David Hirsch, M.D., Ph.D. Managing Partner, Longitude Capital Gare
Slide 4: Setting the Standard for Responsible Pain Management
Setting the Standard Management for Responsible Pain • • Extended-release oxycodone Proprietary abuse-deterrent DETERx® Technology designed to resist crushing, chewing, grinding and injecting 2016 Product Launch • • Novel, dual mechanism of action Extended-release and immediate-release formulations
Slide 5: 2019: A Breakthrough Year
2019: A Breakthrough Year Accelerate Xtampza® ER With Exclusive Payer Wins Maximize Nucynta® Franchise: Leverage the Amended Agreement Strengthen Operational Execution Maintain Strong Financial Performance with Revenue Growth Execute Long Term Growth Strategy Become the Leader in Responsible Pain Ma
Slide 6: Chronic Pain and Opioid Abuse in America: A Serious Healthcare Challenge
Chronic Pain and Opioid Abuse in America: A Serious Healthcare Challenge • Represents more than 20% of adult population • 8% classified with high-impact pain limiting at least one major life activity 50 Million adults suffering from pain in 20161 U.S. chronic • Includes: • direct medical costs • los
Slide 7: Opioids Play a Key Role in Pain Management But Present Their Own Challenges
Opioids Play a Key Role in Pain Management But Present Their Own Challenges Abuse, misuse, and diversion can result in serious consequences. Abuse is common 34% of abusers successfully defeated the abuse-deterrent mechanism of reformulated OxyContin® to snort or inject1 42% of oral abusers using cru
Slide 8: Pain Specialist's View of Collegium Portfolio
Pain Specialist’s View of Collegium Portfolio Most Differentiated Most Favorable Branded ER Opioids 64% 64% 62% 59% Belbuca 61% Butrans 53% Butrans 47% 43% Embeda Embeda 35% 43% Belbuca Morphabond ER 28% Morphabond ER Hyslingla ER 25% Zohydro 22% Zohydro 37% OxyContin Arymo ER 17% 34% Hyslingla ER 1
Slide 9: Xtampza ER Utilizes a Novel Abuse-Deterrent Formulation—DETERx Microsphere Technology
Xtampza® ER Utilizes a Novel Abuse-Deterrent Formulation—DETERx® Microsphere Technology Abuse and Misuse Deterrence Efficacy ER oxycodone with oral, of action unique DETERx abuse-deterrent • Crushing • Grinding • Cutting• Injecting • Chewing DETERx technology However, abuse of is engineered to maint
Slide 10: Xtampza ER vs. OxyContin Head-to-Head PK Data
Xtampza® ER vs. OxyContin® Head-to-Head PK Data Xtampza ER intact and crushed vs. crushed oxycodone IR (oral administration) OxyContin intact and crushed vs. crushed oxycodone IR (oral administration) 80 80 Crushed Xtampza ER microspheres are bioequivalent to intact capsules when taken orally OxyCon
Slide 11: Positive Human Abuse Potential Data
Positive Human Abuse Potential Data Lower Mean: Drug Liking EMAX Lower Mean: Take Drug Again EMAX *P<0.0001 vs. IR oxycodone ‡ P<0.001 vs. IR oxycodone † P<0.01 vs. IR oxycodone *P<0.0001 vs. IR oxycodone † P<0.01 vs. IR oxycodone 87.7 86.4 75 .4† 74 .9* 73.9* 73.3† .8* Intact Chewed Intact Chewed I
Slide 12: Xtampza ER Accelerating Prescription Growth
Xtampza® Accelerating ER Prescription Growth 8 7,700 7,100 8.7 10,000 10.0 7.9 1: Source: IQVIA NPA, Xponent, & Xponent Prescribing Dynamics through September 2018 2: Source: IQVIA NPA Weekly through Dec 21 2018 13 Strong Sequential TRx Growth1 100,000 80,000 60,000 40,000 20,000 0 Q1-17Q2-17Q3-17Q4
Slide 13: 2019 Key Actions to Accelerate Xtampza ER
2019 Key Actions to Accelerate Xtampza® ER Challenge the “Status Quo” – Differentiate Xtampza ER from OxyContin® to become the preferred ER oxycodone for appropriate patients • Focused and impactful HCP messaging to show differentiation from OxyContin (i.e., comparative PK data) • • • Continue inves
Slide 14: Xtampza ER Continues to Win Exclusive Formulary Coverage
Xtampza® ER Continues to Win Exclusive Formulary Coverage covered: ~20% Commercial and ~37% Medicare Part D1 Xtampza ER Exclusive lives 60 50 40 30 20 10 - Dec. 2016 Dec. 2017 Dec. 2018 2019 (Anticipated) 1 MMIT Xtampza ER data September 2018; policies applied 2 IQVIA FIA Data Current 12 Months (Aug
Slide 15: Xtampza ER: New Exclusive ER Oxycodone Formulary Wins Took Effect January 1, 2019
Xtampza® ER: 13 New Exclusive ER Oxycodone Formulary Wins Took Effect January 1, 2019 16 New in 2019 Existing Medicare D Commercial
Slide 16: Maximize the Value of the Nucynta Franchise
Maximize the Value of the Nucynta® Franchise Compelling strategic fit that is aligned to Collegium’s mission of becoming the leader in responsible pain management and broadens our pain management portfolio of meaningfully differentiated products • • • • • • Financially driven transaction that is imm
Slide 17: Nucynta Amendment Improves Collegium's Economics
Nucynta® Amendment Improves Collegium’s Economics • • • • • Collegium’s economics increase at all levels of Net Sales Removes $135.0 million guaranteed annual minimum royalty obligation in future years Expected to reduce liabilities on the balance sheet Enables a tax-efficient structure Collegium co
Slide 18: Nucynta Franchise Viewed Favorably Among Pain Specialists
Nucynta® Franchise Viewed Favorably Among Pain Specialists Based on Market Research Tapentadol is rated as having greater efficacy than other atypical opioids % HCPs low efficacy % HCPs high efficacy Nucynta ER is perceived as most favorable atypical ER opioid product HCPs say Nucynta ER is ‘Highly
Slide 19: 2019 Financial Guidance
2019 Financial Guidance Xtampza® ER Revenue $95.0 – $105.0 Million Nucynta® Franchise Revenue $200.0 – $210.0 Million Total Operating Expenses (Excluding Cost of Product Revenues) $125.0 – $135.0 Million Note: This financial guidance, provided by Collegium Pharmaceutical, Inc. in its Current Report
Slide 20: 2019 Financial Guidance
2019 Financial Guidance Xtampza® ER Revenue $95.0 — $105.0 Million a MEST ese $200.0 — $210.0 Million Revenue Total Operating Expenses $125.0 — $135.0 Million (Excluding Cost of Product Revenues) Note: This nancial guidance, revded by Collegium Pharmaceutical, ne. ns Curent Report on Ferm 8 fied wth
Collegium Pharmaceutical — Investor Presentation (January 2019) on 6ix